Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
OpenNational Institutes of Health · Opportunity number RFA-CA-27-002
Eligibility
Nonprofits are listed as eligible applicants.
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Independent school districts
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- State governments
- Private institutions of higher education
- City or township governments
- Special district governments
- Public and state controlled institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- For profit organizations other than small businesses
- Small businesses
- Native American tribal organizations (other than Federally recognized tribal governments)
- County governments
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Funding
| Total program funding | $5,900,000 |
|---|---|
| Award floor | Not listed |
| Award ceiling | $300,000 |
| Category | Health |
| Assistance listing | 93.394 |
Official sources
Last verified on Grants.gov Nov 4, 2026. Grantvello is not affiliated with Grants.gov or National Institutes of Health. The notice on Grants.gov is the binding text.